Resources for Food and Drug Administration (FDA)

FDA approves Cymbalta for Fibromyalgia

www.upi.com

Eli Lilly and Co. said the U.S. Food and Drug Administration has approved duloxetine HCl, marketed under the name Cymbalta, for fibromyalgia.

The Indianapolis drug maker said Cymbalta is the first serotonin-norepinephrine reuptake inhibitor proven to give relief to patients with the pain disorder.

"The FDA approval of Cymbalta for the management of fibromyalgia is another important step in the efforts to ensure that people with fibromyalgia will have the availability of effective medications to help reduce the chronic, widespread pain of this life-altering disorder," Lynne Matallana, president of the National Fibromyalgia Association, said in a statement.

View the Resource

Share or bookmarklet this web page at: